BMS-986020 sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
| Molecular Weight | 504.51 |
| CAS Number | 1380650-53-2 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage | 2-8°C, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related LPL Receptor Products |
|---|
| BMS-986234
BMS-986234 is a lysophosphatidic acid receptor-1 (LPA1) antagonist with a Kb value of 2.8 ± 0.4 nM. |
| BMS-986337
BMS-986337 is a lysophosphatidic acid receptor (LPAR1) antagonist for studies related to pulmonary fibrosis. |
| DJS-002
DJS-002 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
| HL001
HL001 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
| LTSE-2578
LTSE-2578 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
